Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

PK/PD of XM22 in Children With Ewing Family of Tumors or Rhabdomyosarcoma

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Teva Pharmaceutical Industries ( Merckle GmbH )
ClinicalTrials.gov Identifier:
NCT01585649
First received: April 18, 2012
Last updated: May 17, 2016
Last verified: May 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: April 2015
  Primary Completion Date: June 2014 (Final data collection date for primary outcome measure)